Preclinical and clinical development of a first-in-class, innovative, bispecific immunotherapeutic agent as a drug candidate in cancer immunotherapy 

Funding Agreement No.: POIR.01.01.01-00-0429/19-00 under Measure 1.1: “R&D projects of companies”

Date of the contract conclusion: 07/11/2019

The aim of this project is to develop a first-in-class, innovative, safe and clinically efficacious bispecific protein format (VHHH/VH, scFv or Fab), allowing for targeting both the PD-1/PD-L1 immune response pathway and selected growth factor receptors, and to validate it in the course of phase I and phase II of clinical trials as a drug candidate for the treatment of solid tumours.

Total value of the project: PLN 43,674,858.55
Total value of funding: PLN 26,735,921.11